Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List

Stock News12-08

Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as "Jinpei Growth Hormone Injection") and the co-introduced Meishiya (commonly known as "Megestrol Acetate Oral Suspension").

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153111707?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 16:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153111707","market":"sg","top_or_hot":-1,"title":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List","media":"Stock News","content":"<p>Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as \"Jinsai Pharmaceutical\") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as \"Jinpei Growth Hormone Injection\") and the co-introduced Meishiya (commonly known as \"Megestrol Acetate Oral Suspension\").</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 16:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as \"Jinsai Pharmaceutical\") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as \"Jinpei Growth Hormone Injection\") and the co-introduced Meishiya (commonly known as \"Megestrol Acetate Oral Suspension\").</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1153111707","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153111707","pubTimestamp":1765184295,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"91272":"长春高新技术产业(集团)股份有限公司（临时代码）","BK0239":"医药制造","BK0028":"国家队","BK0057":"长吉图板块","000661":"长春高新","BK0075":"新三板","BK0188":"融资融券","BK0046":"生物疫苗"},"translate_title":"长春高新技术产业（集团）有限责任公司。（000661.SZ）子公司有两种药品新纳入国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91272":1,"000661":1},"content_text":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as \"Jinsai Pharmaceutical\") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as \"Jinpei Growth Hormone Injection\") and the co-introduced Meishiya (commonly known as \"Megestrol Acetate Oral Suspension\").","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153111707","isCrawlerRequest":true}